1. Home
  2. IMCR vs FORTY Comparison

IMCR vs FORTY Comparison

Compare IMCR & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$29.68

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Formula Systems (1985) Ltd.

FORTY

Formula Systems (1985) Ltd.

N/A

Current Price

$118.15

Market Cap

1.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMCR
FORTY
Founded
2008
1985
Country
United Kingdom
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2016
1998

Fundamental Metrics

Financial Performance
Metric
IMCR
FORTY
Price
$29.68
$118.15
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $62.73
N/A
AVG Volume (30 Days)
★ 364.8K
2.6K
Earning Date
11-05-2026
11-19-2026
Dividend Yield
N/A
★ 9.99%
EPS Growth
★ 30.39
N/A
EPS
★ 0.23
N/A
Revenue
★ $249,428,000.00
N/A
Revenue This Year
$13.06
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
$132.78
★ $36.65
Revenue Growth
★ 43.05
N/A
52 Week Low
$27.56
$102.01
52 Week High
$40.71
$190.56

Technical Indicators

Market Signals
Indicator
IMCR
FORTY
Relative Strength Index (RSI) 28.05 52.29
Support Level $27.66 $115.00
Resistance Level $30.21 $119.68
Average True Range (ATR) 1.17 1.58
MACD -0.20 -0.24
Stochastic Oscillator 5.03 47.05

Price Performance

Historical Comparison
IMCR
FORTY

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

Share on Social Networks: